meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
versus all
vs VEGF(R) inhibitor
vs sunitinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus bevacizumab
title
sunitinib
title
IMmotion-151 (PDL1 >1%), 2019 NCT02420821 mRCC - L1 - PDL1 positive 178/184
IMmotion-150 (AtB - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 50/60
Pathology:
mRCC - L1 - PDL1 positive;
mRCC - L1 - PDL1 positive
IMmotion-151 (PDL1 >1%), 2019
IMmotion-150 (AtB - PDL1>1%), 2018
atezolizumab plus bevacizumab
2
T1
T1
sunitinib
0
T0
T0